Core Scientific, Inc.
CORZQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.41 | 0.03 |
| FCF Yield | 1.81% | 0.94% | 5.35% | 16.14% |
| EV / EBITDA | 35.31 | -72.98 | 5.89 | 11.70 |
| Quality | ||||
| ROIC | 2.53% | -2.23% | 1.59% | -0.64% |
| Gross Margin | 27.69% | 13.66% | 29.12% | 16.98% |
| Cash Conversion Ratio | -0.11 | -0.13 | 8.85 | -1.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.65% | 21.83% | 51.36% | 93.94% |
| Free Cash Flow Growth | 292.24% | -84.98% | -7.16% | 175.92% |
| Safety | ||||
| Net Debt / EBITDA | 21.01 | -54.75 | -0.57 | -1.15 |
| Interest Coverage | 0.11 | -5.48 | 0.00 | -23.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.68 | 4.69 | 4.59 |
| Cash Conversion Cycle | -134.00 | 12.28 | -33.93 | -25.52 |